摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

达美司特 | 71680-63-2

中文名称
达美司特
中文别名
达美卓斯
英文名称
2,4-Diamino-7-methyl-pyrazol<1,5-a>-s-triazin
英文别名
7-methyl-pyrazolo[1,5-a][1,3,5]triazine-2,4-diamine;dametralast;7-methylpyrazolo[1,5-a][1,3,5]triazine-2,4-diamine
达美司特化学式
CAS
71680-63-2
化学式
C6H8N6
mdl
MFCD00865709
分子量
164.17
InChiKey
CDMRMPWJHYFXJJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -0.2
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.166
  • 拓扑面积:
    95.1
  • 氢给体数:
    2
  • 氢受体数:
    5

安全信息

  • 海关编码:
    2933990090

文献信息

  • Pharmaceutical preparation comprising an active dispersed on a matrix
    申请人:——
    公开号:US20040058896A1
    公开(公告)日:2004-03-25
    The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.
    本发明涉及制药技术领域,描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中,活性成分基本上均匀地分散在由脂肪醇甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
  • Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
    申请人:Scaramuzzino, Giovanni
    公开号:EP1336602A1
    公开(公告)日:2003-08-20
    New pharmaceutical compounds of general formula (I): F-(X)q where q is an integer from 1 to 5, preferably 1; -F is chosen among drugs described in the text, -X is chosen among 4 groups -M, -T, -V and -Y as described in the text. The compounds of general formula (I) are nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without hypotensive side effects and for this reason they are useful for the preparation of medicines for prevention and treatment of inflammatory, ischemic, degenerative and proliferative diseases of musculoskeletal, tegumental, respiratory, gastrointestinal, genito-urinary and central nervous systems.
    通式(I)的新药物化合物:F-(X)q,其中q是1到5的整数,最好是1;-F是在文本中描述的药物中选择的,-X是在文本中描述的4个组-M,-T,-V和-Y中选择的。通式(I)的化合物是硝酸盐前药,可以在体内以受控和选择性的方式释放一氧化氮,而不会产生降压副作用,因此它们非常适用于制备用于预防和治疗肌肉骨骼,皮肤,呼吸,消化,泌尿和中枢神经系统的炎症,缺血,退行性和增生性疾病的药物。
  • Diagnostic/therapeutic agents
    申请人:Klaveness Jo
    公开号:US20050002865A1
    公开(公告)日:2005-01-06
    Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.
    可定位的诊断和/或治疗活性剂,例如超声对比剂,包括悬浮在载体液中的报告物,该报告物包含含气体或生成气体的材料,该剂能够与目标形成至少两种结合对。
  • Benzofuran derivatives
    申请人:MERCK FROSST CANADA INC.
    公开号:EP0338782A1
    公开(公告)日:1989-10-25
    Benzofuran derivatives are useful as inhibitors of mammalian leuktoriene biosynthesis. As such, these compounds are useful therapeutic agents for treating allergic conditions, asthma, cardiovascular disorders, inflammation. The compounds are also useful as analgesics and as cytoprotective agents, and for these uses are made into pharmaceutical compositions. The compounds of the invention have the formula wherein: each R1 is independently hydrogen or C1 to C6 alkyl; R2 is hydrogen, C1 to C8 alkyl, -(CH2)n-het-Y, -(CH2)n-Q or - CH- Q, CH3 where Q is R3 is hydroxyl, , OCOCH2CH2COOH, OSO3H, or OPO3H2; each R4 is independently C1 to C6 alkyl; each R5 is independently H, C1 to C6 alkyl, or both R5s join to form a 5- or 6-membered ring with the N to which they are attached; Het is a heterocyclic group selected from pyridine, pyrazine, pyrimidine, oxazole, pyrazole, oxadiazole, tetrazole, quinoline, thiophene, furan, pyrrole, thiazole, thiadiazole, or imidazole; X is 0, S, SO, SO2; Y, Y1, Y2, Y3, Y4 and Z are each independently H, halogen, OH. C1 to C6 alkyl, C2 to C6 alkenyl, C1-6hydroxyalkyl, -COOR1, -COR1, nitro, carboxy (C1-6alkyl), C1 to C6 alkoxy, C1 to C6 alkylthio, -CH2SR1, OCH2CO2R1, and each n is independently 0 to 10; with the provisos that: (a) not all of R1, R2, Y, Y1, Y2, Y3, Y4, and Z are simultaneously H; (b) when up to 2 of R1, R2, Y, Y1, and Z are C1 to C2 alkyl, and the others of R1, R2, Y, Y1, and Z are H, then R3 is not OH; and (c) when n in is O and one of R3, Y, Y1 or Z is OH, then Ri is not H or Ci to C2 alkyl; or are acid-addition salts thereof.
    苯并呋喃生物可作为哺乳动物白细胞介素生物合成的抑制剂。因此,这些化合物是治疗过敏症、哮喘、心血管疾病和炎症的有效药物。这些化合物还可用作镇痛剂和细胞保护剂,并可用于制成药物组合物。本发明的化合物具有如下式子 其中 每个 R1 独立地为氢或 C1 至 C6 烷基; R2 是氢、C1 至 C8 烷基、-(CH2)n-het-Y、-( )n-Q 或-CH- Q, CH3 其中 Q 是 R3 是羟基、 OCO COOH、OSO3H 或 OPO3H2;每个 R4 独立地是 C1 至 C6 烷基; 每个 R5 独立地为 H、C1-C6 烷基,或两个 R5 与所连接的 N 连接形成 5 或 6 元环; Het 是杂环基团,选自吡啶吡嗪嘧啶噁唑吡唑、噁二唑、四唑喹啉噻吩呋喃吡咯噻唑噻二唑咪唑; X 是 0、S、SO、SO2; Y、Y1、Y2、Y3、Y4 和 Z 各自独立地是 H、卤素、OH C1-C6烷基、C2-C6烯基、C1-6羟基烷基、-COOR1、-COR1、硝基、羧基(C1-6烷基)、C1-C6烷氧基、C1-C6烷基、- SR1、O CO2R1、 且每个 n 独立地为 0 至 10;但有以下条件: (a) 并非所有 R1、R2、Y、Y1、Y2、Y3、Y4 和 Z 同时都是 H; (b) 当 R1、R2、Y、Y1 和 Z 中最多有 2 个是 C1 至 C2 烷基,而 R1、R2、Y、Y1 和 Z 中的其它是 H 时,则 R3 不是 OH;以及 (c) 当 n 为 O 且 R3、Y、Y1 或 Z 中的一个为 OH 时,则 Ri 不是 H 或 Ci 至 C2 烷基;或为其酸加成盐。
  • Etchant, replenishment solution and method for forming copper wiring
    申请人:MEC COMPANY LTD.
    公开号:US10174428B2
    公开(公告)日:2019-01-08
    An etchant for copper includes an acid and one or more compounds selected from the group consisting of an aliphatic noncyclic compound, an aliphatic heterocyclic compound and a heteroaromatic compound. The aliphatic noncyclic compound is a saturated aliphatic noncyclic compound (A) including only two or more nitrogen atoms as heteroatoms, and 2 to 10 carbon atoms. The aliphatic heterocyclic compound is a compound (B) including a five-, six-, or seven-membered ring having one or more nitrogen atoms as one or more heteroatoms constituting the ring. The heteroaromatic compound is a compound (C) including a six-membered heteroaromatic ring having one or more nitrogen atoms as one or more heteroatoms constituting the ring.
    的蚀刻剂包括酸和一种或多种选自脂肪族非环化合物、脂肪族杂环化合物和杂芳香族化合物的化合物。脂肪族非环化合物是饱和脂肪族非环化合物 (A),只包括两个或两个以上的氮原子作为杂原子,以及 2 至 10 个碳原子。脂族杂环化合物是一种化合物(B),包括一个五元环、六元环或七元环,其中有一个或多个氮原子作为构成环的一个或多个杂原子。杂芳香族化合物是一种化合物(C),包括一个六元杂芳香环,该环具有一个或多个氮原子作为构成环的一个或多个杂原子。
查看更多

同类化合物

酪氨酸,2-甲氧基-O-甲基- 达美司特 百里酚-6-磺化三(2-羟基乙基)铵 吡唑并[1,5-a][1,3,5]噻嗪-4(3H)-酮 吡唑并[1,5-a][1,3,5]三嗪-2,4-二胺 吡唑并[1,5-a]-1,3,5-三嗪-4-胺,N-羟基- 吡唑并[1,5-D][1,2,4]三嗪酮 吡唑并[1,5-A]-1,3,5-三嗪-2,4(1H,3H)-二酮 N4-(1,1-二甲基乙基)-7-甲基吡唑并(1,5-a)-1,3,5-三嗪-2,4-二胺盐酸盐 N'-甲酰基-4-氨基吡唑并[5,1-c][1,2,4]三嗪-3-甲酰肼 8-苄基-2-甲基-4-(N-甲基氨基)吡唑并[1,5-a]-1,3,5-三嗪 8-碘-1H,4H-吡唑并[1,5-a][1,3,5]三嗪-4-酮 8-溴-4-氯-2-(甲基硫代)吡唑并[1,5-a][1,3,5]三嗪 8-溴-2-(甲基硫代)吡唑并[1,5-a][1,3,5]噻嗪-4-醇 8-溴-2,7-二甲基-3H-吡唑并[1,5-a][1,3,5]噻嗪-4-酮 8-溴-1H,4H-吡唑并[1,5-a][1,3,5]三嗪-4-酮 7-甲基-吡唑并[1,5-a]-1,3,5-三嗪-4(1H)-酮 7-甲基-6H-吡唑并[4,5-e][1,2,3]三嗪-4-酮 7-甲基-1,7-二氢-4H-吡唑并[3,4-d][1,2,3]三嗪-4-酮2-氧化物 7-(叔丁基)吡唑并[1,5-a][1,3,5]三嗪-4(3H)-酮 5-二乙基氨基甲基-2-苯基呋喃-3-羧酸 5,6-二氢吡唑并[1,5-d][1,2,4]三嗪-4,7-二酮 4-甲氧基吡唑并[1,5-a][1,3,5]三嗪 4-氯-2-(甲硫基)吡唑并[1,5-a][1,3,5]三嗪 4-氨基-7-甲基吡唑并[5,1-C][1,2,4]三嗪-3-甲腈 4,7-二甲基吡唑并[5,1-c][1,2,4]三嗪-3-羧酸乙酯 4,7-二甲基吡唑并[5,1-C][1,2,4]三嗪-3-羧酸 4,6-二氢-6-(碘乙酰基)-3-甲基-4-亚甲基吡唑并[5,1-c][1,2,4]三嗪 3-甲氧基-2H-吡唑并[4,3-e][1,2,4]三嗪 3-(1,1-二甲基乙基)-7-(5-甲基-3-异恶唑基)-2-[(1-甲基-1H-1,2,4-三唑-5-基)甲氧基]吡唑并[1,5-d][1,2,4]三嗪 3,4-二甲基吡唑并[5,1-c][1,2,4]三嗪 2-甲基吡唑并[1,5-d][1,2,4]三嗪-4(5H)-酮 2-甲基吡唑并[1,5-a][1,3,5]三嗪-4(1H)-酮 2-甲基-4-(N-甲基氨基)-8-[(2-噻吩基)甲基]吡唑并[1,5-a]-1,3,5-三嗪 2-氨基吡唑并[1,5-a][1,3,5]三嗪-4(1H)-酮 2-Thi氧代-2,3-二氢吡唑并[1,5-a][1,3,5]噻嗪-4(1H)-酮 2-(甲基硫代)吡唑并[1,5-a][1,3,5]噻嗪-4(3H)-酮 2,4-二氨基-吡唑并(1,5-a)-S-三嗪盐酸盐半水合物 2,4-二(甲基氨基)-7-甲基吡唑并(1,5-a)-S-三嗪 1-(4,7-二甲基吡唑并[5,1-c][1,2,4]三氮杂-3-基)-1-乙酮 4-chloro-2-methylpyrazolo[1,5-a][1,3,5]triazine 8,9-Bis-(2-furyl)furo<3,2-d>-s-triazolo<4,3-c>pyrimidin N,N-dimethyl-N'-[7-methyl-3-(5-nitro-furan-2-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-yl]-formamidine (8-chloro-7-methyl-pyrazolo[1,5-a][1,3,5]triazin-4-yl)-methyl-amine methyl-phosphonothioic acid O-isopropyl ester O'-{1-[6-oxo-4-(1,1,2,2-tetrafluoro-ethoxy)-phenyl]-1,6-dihydro-pyridazin-3-yl} ester 9-bromo-3-phenyl-pyridazino[1,6-a][1,3,5]triazine-2,4-dione prop-2-ynyl 5-(1H-benzo[d][1,2,3]triazol-5-yl)-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbimidate hydrochloride 6-Acetyl-3-methyl-4-methylen-pyrazolo<3,2-c>-as-triazin 2-Methylamino-5,7-dimethyl-s-triazolo<2,3-c>pyrimidin ethyl 7-benzamido-3-tert-butyl-4-oxo-4,6-dihydropyrazolo[5,1-c][1,2,4]triazine-8-carboxylate